Immix Biopharma reported an interim update on September 29 from NEXICART-2, its registrational-design study of the CAR-T therapy NXC-201 in relapsed or refractory AL amyloidosis, and the headline number is an 89 percent complete response rate across all 45 enrolled patients, assessed by an independent review committee. All 25 of the most recently treated patients are either in complete response or have no detectable residual disease in their bone marrow. The company also reported no relapses among patients who reached complete response or minimal residual disease negativity, no neurotoxicity, and no cases of enterocolitis.
The same day, the company priced a $125 million equity offering at $11.00 a share. The sequencing was not a coincidence: in biotech, data are the asset that buys the financing that buys the next trial, and a late-stage readout is the moment when the price of capital is set. Immix raised on an 89 percent number and a four-patient projection that it could become 98 percent. Understanding which parts of that are measured and which parts are expected is the difference between reading the data and reading the pitch.
What the interim update measured
NEXICART-2 (NCT06097832) is a 45-patient, multi-site United States Phase 2 study of NXC-201 in people whose AL amyloidosis has come back or stopped responding to prior treatment. The 89 percent figure is 40 of 45 patients in complete response, and the review was conducted by an independent committee rather than by the company's own investigators, a distinction that matters in a disease where response assessment involves bone marrow biopsies and organ response criteria.
NXC-201 is a CAR-T directed at BCMA, the protein that marks the plasma cells producing the toxic light chains at the center of the disease. The therapy's distinguishing engineering feature, as the company describes it, is a modified signaling domain and binder designed to filter out activation that does not come from its target, an attempt to reduce the off-tumor inflammation that drives the class's most feared toxicities. That design claim is the link the company draws between the mechanism and the safety observations it is highlighting, and it is a claim the final readout will either strengthen or complicate.
Within the 25 most recently treated patients, 21 are in complete response and 4 are MRD-negative, meaning the malignant plasma cells that make the toxic light chains can no longer be detected in their bone marrow at the assay's sensitivity. Because MRD negativity in this trial has preceded complete response in every patient who reached it, the company projects that those four will convert, which would lift the rate to 98 percent, or 44 of 45.
That leaves one patient among the 45 who is neither in complete response nor MRD-negative. One patient is a rounding error at this sample size, and it is also the reminder that the projection has an arithmetic ceiling. The honest way to describe the 98 percent is as the top of a range the company can defend, contingent on four conversions that have not happened yet, in a study whose final readout is still more than half a year away.
The MRD measure deserves its own explanation, because it is doing a lot of work in this update. The light chains that clog organs in AL amyloidosis are produced by clonal plasma cells in the bone marrow, so the depth of a response can be measured by whether those cells are still detectable. Clearing them below an assay's threshold does not by itself guarantee that organ function will recover, and it does not prove the clone is gone for good, but in this trial every patient who reached that threshold went on to meet the complete response criteria within a year. That observed sequence is the basis for treating MRD negativity as a leading indicator rather than a separate achievement, and it is why the company can discuss 98 percent without walking back the 89 percent it measured.
The rate has moved as the cohort has grown
An earlier interim, reported in May with 20 patients assessed, put the complete response rate at 95 percent. The larger dataset reads 89 percent, and the company's explanation is visible in the structure of the update rather than in its rhetoric. The 25 new patients were treated more recently and have shorter follow-up, so some of them sit in the MRD-negative-but-not-yet-CR category that the conversion history says is a waypoint, not a destination. As follow-up matures, each unconverted patient has room to move up. The rate can rise without any new patient responding.
That is a real mechanism, and it is also the reason the headline number needs a time axis attached to it. A response rate in a disease treated with a one-time therapy is a moving quantity: it changes both with who is enrolled and with how long anyone has been watched. The May number and this number describe different amounts of follow-up as well as different patients, and the only comparison that will be clean is the final readout, when the last patient enrolled has had time to convert or not.
Durability is the claim a one-time therapy has to earn
The commercial case for NXC-201 rests on a word the company uses in nearly every communication: one-and-done. The standard first-line regimen for AL amyloidosis is a daratumumab-based combination given over many months, and patients who relapse work through successive lines of therapy for as long as they can tolerate them. The company's chief executive, Ilya Rachman, frames the alternative his drug is aimed at as years of burdensome, continuous treatment. Replacing that with a single treatment course would change what the disease costs a patient in time, clinic visits, and drug exposure, and it would matter most in a disease where the organs being damaged are the heart, the kidneys, and the liver, and where the damage compounds.
Durability is therefore the number that decides whether the company is right. Immix reports that no patient who reached complete response or MRD negativity has relapsed to date. The phrase to notice is to date. Of the 45 patients in the study, 25 are new, which means the durability observation is concentrated in the earlier cohort, and each newly treated patient adds a shorter follow-up period to the denominator. A therapy priced on the promise of lasting remission has to be judged on years, and this dataset cannot supply them yet.
The safety profile carries a similar shape. The company reports no neurotoxicity and no enterocolitis to date, which for a BCMA-directed CAR-T is a notable claim, since the cell therapies in this class are shadowed by those risks. Both statements are bounded by the same date, and the final readout will extend them across a longer observation window and the full enrolled population. Nothing in the interim suggests the profile is deteriorating. It simply does not yet cover the horizon that one-and-done implies.
The financing is part of the clinical story
The $125 million offering priced at $11.00 a share, roughly a 4 percent discount to the prior close, for about 11.36 million shares, implying dilution near 16 percent, with J.P. Morgan as sole book-running manager and a close expected on September 30. The company ended June with about $232 million in cash and short-term investments, and it has told investors the raise extends its runway from mid-2028 to the first quarter of 2029. The proceeds are earmarked for NXC-201 development, working capital, and general corporate purposes, which is the standard allocation and also the honest one: the final readout and a BLA submission are planned for mid-2027, and approval and launch would sit entirely inside the funded period.
The raise continues a pattern of selling into strength. A December 2025 offering brought in roughly $94 million at $5.10 a share, and a May 2026 offering raised about $140.65 million at $8.94. Each raise followed a data point and preceded the next. For investors who bought the earlier rounds, the September offering at $11 is the first in which the price has stepped up materially between data cycles, which is one way of measuring how the market has repriced the program.
It is also worth reading the offering against the company's own history in 2026. A Mavengity report in July described how a person using the same name as a man on Rhode Island's most-wanted list was reportedly hired as the company's chief medical officer, an episode that raised questions about executive screening at small biotechs generally. The clinical question and the governance question are separate, and the offering priced into a market that has been given both to weigh.
What the final readout has to show
The path to a filing runs through the same 45 patients. Immix plans a final readout and a BLA submission in mid-2027, and the designations already in hand, Breakthrough Therapy and Regenerative Medicine Advanced Therapy from the FDA, Orphan Drug from the FDA and the European Medicines Agency, are signals that regulators have accepted the program's seriousness rather than evidence about the data. What those regulators will weigh at filing is the durability question above, the conversion of the four pending patients, and whether an independently reviewed complete response rate in the high eighties survives a longer look at the same patients.
The disease context sets the stakes. Immix cites an analysis in the Blood Cancer Journal projecting roughly 30,500 people in the United States with relapsed or refractory AL amyloidosis in 2026, growing about 12 percent a year, and it describes the amyloidosis market as growing from $6.2 billion in 2025 to $6.6 billion in 2026. Those figures are the company's market case and should be read as such. The clinical case is simpler: the disease kills people through organ failure when treatment stops working, the current standard of care demands continuous treatment, and 89 percent complete response in a relapsed population is a number that no approved regimen has delivered.
That is why the financing and the data arrived together. The company has roughly 18 months of funded operation and one readout standing between it and a filing, and the entire investment case rests on whether a response rate that has drifted from 95 to 89 as it matured settles at a level the FDA will accept as evidence. The four pending patients will move the number first. The durability data will decide what it means.
Primary sources
- Immix Biopharma, Exhibit 99.1 to the September 29, 2026 Form 8-K, for the interim NEXICART-2 results, the complete response and MRD-negative counts, the safety observations, and the regulatory timeline.
- ClinicalTrials.gov, NEXICART-2 trial record, for the trial design and enrollment.
- Edison Group, Immix Biopharma: 89% complete response rate and $125m offering, September 2026, for the offering terms and the runway guidance.
- Mavengity, the Immix executive screening investigation, July 21, 2026, for the July governance reporting.